Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Aims:

1. To pilot an randomized, controlled trial (RCT) to assess the effectiveness of the commonly prescribed medications in UK general practice for IBS: mebeverine (anti-spasmodic) and methylcellulose (bulking-agent) and of the patient CBT based self-management website.

2. To assess the level of support needed for patients using the patient CBT based self-management website for IBS (i.e., initial 30 minute telephone support session with a nurse and email support or not).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hazel Everitt
• Collaborator: National Institute for Health Research, United Kingdom
• Treatments: Alverine; Mebeverine

Criteria

Inclusion Criteria:

• Patients aged 16 to 60 years with symptoms of irritable bowel syndrome that fulfill the Rome III criteria

Exclusion Criteria:

• Atypical symptoms (unexplained weight loss, rectal bleeding)

• Diagnosis of inflammatory bowel disease, coeliac disease or peptic ulcer disease

• Pregnant or breast feeding

• Currently taking or allergy to mebeverine or methylcellulose